Medicinal Products

ACTIVEED ALLERGY CETIRIZINE 10 mg

Generic drug of the therapeutic class: Allergology
active ingredients: Cetirizine
Lab: Johnson & Johnson Sante Bea

Divisible coated tablet
Box of 7
All forms

Indication

In adults and children 6 years and older:

· Cetirizine is indicated for the treatment of nasal and ocular symptoms of seasonal and perennial allergic rhinitis.

· Cetirizine is indicated for the treatment of symptoms of chronic idiopathic urticaria.

Medical advice is recommended for chronic idiopathic urticaria.

Dosage ACTIFED ALLERGY CETIRIZINE 10 mg Film-coated tablet scored box of 7

Children from 6 to 12 years: 5 mg twice a day (half a tablet twice a day).

Adults and adolescents over 12 years of age: 10 mg once daily (one tablet).

The tablets should be swallowed with a drink.

Elderly: There is no need to adjust the dosage in elderly patients with normal renal function.

Moderate to severe renal impairment: The available data do not allow documentation of benefit / risk in renal failure. Due to its essentially renal elimination (see section 5.2 ), and if it can not be used as an alternative treatment, cetirizine will be administered in these situations by adjusting the dosage and the spacing between catches as a function of clearance. renal according to the table below.

The clearance of creatinine (CLcr) can be estimated (in ml / min) from the measurement of serum creatinine (in mg / dl) according to the following formula:

CL cr = [140- age (year)] x weight (kg) x (0.85 for women)

72 x serum creatinine (mg / dl)

Dosage adjustment in patients with renal impairment:

Group

Creatinine clearance (ml / min)

Dose and frequency of administration

Normal kidney function

Mild renal insufficiency

Moderate renal insufficiency

Severe renal insufficiency

End stage renal failure and dialysis patients

≥ 80

50-79

30-49

<30

<10

10 mg once a day

10 mg once a day

5 mg once a day

5 mg once every 2 days

Against-indicated

In children with renal impairment, the dosage will be adjusted individually according to the renal clearance, age, and body weight of the patient.

Hepatic impairment: no dose adjustment is necessary in patients with isolated hepatic impairment.

In patients with hepatic impairment associated with renal impairment, a dose adjustment is recommended (see section "Moderate to severe renal impairment" above).

Against indications

· Known hypersensitivity to the active substance, to any of the excipients, to hydroxyzine or to piperazine derivatives.

· Severe renal insufficiency with creatinine clearance less than 10 ml / min.

· This medication is not recommended in patients with congenital galactosemia, glucose-galactose malabsorption syndrome, or lactase deficiency.

Adverse effects Actifed Allergy Cetirizine

Minor adverse effects on the central nervous system including somnolence, fatigue, dizziness and headache were observed in clinical trials with cetirizine at the recommended dose. In a few cases, a paradoxical effect of stimulation of the central nervous system has been observed.

Despite its selective antagonistic effect on peripheral H1 receptors and the relatively low anticholinergic activity, isolated cases of voiding difficulty, accommodation problems and dryness of the mouth have been reported.

Cases of abnormal hepatic function with increased liver enzymes associated with increased bilirubin have been reported. In most cases, abnormalities decreased with cessation of treatment with cetirizine dihydrochloride.

Clinical tests

More than 3, 200 subjects exposed to cetirizine were included in double-blind controlled clinical trials or pharmaco-clinical trials comparing cetirizine to the recommended 10 mg daily dose, placebo or other antihistamines, during which quantified tolerance data are available.

In this population as a whole, adverse events reported in placebo-controlled trials with an incidence of 1.0% or greater were:

Undesirable effect

(WHO-ART)

Cetirizine 10 mg

n = 3260)

Placebo

(n = 3061)

General condition disorders

Tired

1.63%

0.95%

Central and Peripheral Nervous System Disorders

Fear of heights

headaches

1.10%

7.42%

0.98%

8.07%

Gastrointestinal system disorders

Abdominal pain

Dryness of the mouth

Nausea

0.98%

2.09%

1.07%

1.08%

0.82%

1.14%

Psychiatric disorders

Drowsiness

9.63%

5.00%

Respiratory disorders

Pharyngitis

1.29%

1.34%

Drowsiness was statistically more frequent than placebo, but mild to moderate in most cases. Objective tests, validated by other studies, have shown, in the healthy young volunteer, that the usual daily activities are not assigned to the recommended daily dose.

Adverse reactions reported with an incidence of 1% or more in children aged 6 months to 12 years included in placebo-controlled clinical trials or in pharmaco-clinical studies are:

Undesirable effect

(WHO-ART)

Cetirizine 10 mg

(n = 1656)

Placebo

(n = 1294)

Gastrointestinal system disorders

Diarrhea

1.0%

0.6%

Psychiatric disorders

Drowsiness

1.8%

1.4%

Respiratory disorders

rhinitis

1.4%

1.1%

General condition disorders

Tired

1.0%

0.3%

Adverse reactions reported since marketing

In addition to the undesirable effects reported in clinical trials and listed above, isolated cases of adverse events have been reported since the product was marketed. For these less commonly reported adverse events, the frequency estimate (infrequent: ≥ 1/1000 and <1/100, rare: ≥ 1/10000 and <1/1000, very rare: <1/10 000 ) is based on marketing data.

Hematological and lymphatic system disorders:

Very rare: thrombocytopenia

Immune system disorders:

Rare: hypersensitivity

Very rare: anaphylactic shock

Psychiatric disorders:

Uncommon: agitation

Rare: aggression, confusion, depression, hallucination, insomnia

Very rare: tic

Nervous system disorders:

Uncommon: paresthesia

Rare: convulsions, abnormal movements

Very rare: dysgeusia, syncope, tremors, dystonia, dyskinesia

Eye disorders:

Very rare: disturbances of accommodation, blurred vision oculogyric crises

Heart conditions:

Rare: tachycardia

Gastrointestinal disorders:

Uncommon: diarrhea

Hepatobiliary disorders:

Rare: abnormal liver function (increased liver enzymes: transaminases, alkaline phosphatase, gamma-GT and bilirubin)

Skin and subcutaneous tissue disorders:

Uncommon: pruritus, rash

Rare: urticaria

Very rare: angioneurotic edema, fixed pigmented erythema

Renal and urinary disorders:

Very rare: dysuria, enuresis

General disorders and administration site defects:

Uncommon: asthenia, malaise

Rare: edema

investigations:

Rare: weight gain.

Popular Posts

Category Medicinal Products, Next Article